This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Dec. 2, 2013 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will be presenting at the Piper Jaffray 25
th Annual Healthcare Conference at The New York Palace Hotel in
New York City.
The presentation at the Piper conference is scheduled for
12:10 pm EST (
9:10 am PST) on
Tuesday, December 3, 2013. The presentation will be webcast, and the webcast can be accessed via the Investor Relations page of the Depomed website at
www.depomed.com. A recording of the webcast will be archived for 30 days on the company's website.
Depomed, Inc. is a specialty pharmaceutical company that commercializes products for pain and neurology related disorders. Gralise® (gabapentin) is a once-daily treatment approved for the management of postherpetic neuralgia. Zipsor® (diclofenac potassium) Liquid Filled Capsules is a non-steroidal anti-inflammatory drug indicated for relief of mild to moderate acute pain in adults. Lazanda® (fentanyl) Nasal Spray is an intranasal fentanyl drug used to manage breakthrough pain in adults (18 years of age or older) who are already routinely taking other opioid pain medicines around-the-clock for cancer pain. Gralise and other products and product candidates are formulated with Depomed's proven, proprietary Acuform® drug delivery technology. Additional information about Depomed may be found at
August J. Moretti Depomed, Inc. 650-462-5900
SOURCE Depomed, Inc.